SPIRONOLACTONE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for spironolactone and what is the scope of freedom to operate?
Spironolactone
is the generic ingredient in three branded drugs marketed by Cmp Dev Llc, Amneal, Pfizer, Accord Hlthcare, Actavis Elizabeth, Amneal Pharms, Ascot, Aurobindo Pharma, Chartwell Rx, Ivax Pharms, Jubilant Generics, Lederle, Mutual Pharm, Mylan, Norvium Bioscience, Oxford Pharms, Purepac Pharm, Sun Pharm Industries, Superpharm, Upsher Smith, Vangard, Warner Chilcott, Watson Labs, and Zydus Pharms, and is included in twenty-six NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Spironolactone has four patent family members in four countries.
There are sixteen drug master file entries for spironolactone. Forty-three suppliers are listed for this compound.
Summary for SPIRONOLACTONE
International Patents: | 4 |
US Patents: | 8 |
Tradenames: | 3 |
Applicants: | 24 |
NDAs: | 26 |
Drug Master File Entries: | 16 |
Finished Product Suppliers / Packagers: | 43 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 263 |
Patent Applications: | 6,666 |
Drug Prices: | Drug price trends for SPIRONOLACTONE |
Drug Sales Revenues: | Drug sales revenues for SPIRONOLACTONE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SPIRONOLACTONE |
What excipients (inactive ingredients) are in SPIRONOLACTONE? | SPIRONOLACTONE excipients list |
DailyMed Link: | SPIRONOLACTONE at DailyMed |
Recent Clinical Trials for SPIRONOLACTONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
CMP Development, LLC | Phase 4 |
University of California, San Francisco | Phase 2 |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) | N/A |
Pharmacology for SPIRONOLACTONE
Drug Class | Aldosterone Antagonist |
Mechanism of Action | Aldosterone Antagonists |
Medical Subject Heading (MeSH) Categories for SPIRONOLACTONE
Anatomical Therapeutic Chemical (ATC) Classes for SPIRONOLACTONE
Paragraph IV (Patent) Challenges for SPIRONOLACTONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CAROSPIR | Oral Suspension | spironolactone | 25 mg/5 mL | 209478 | 1 | 2020-12-31 |
US Patents and Regulatory Information for SPIRONOLACTONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Accord Hlthcare | SPIRONOLACTONE | spironolactone | TABLET;ORAL | 203512-001 | Sep 19, 2016 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Pfizer | ALDACTONE | spironolactone | TABLET;ORAL | 012151-010 | Dec 30, 1983 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Amneal Pharms | SPIRONOLACTONE | spironolactone | TABLET;ORAL | 091426-001 | Jul 2, 2010 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for SPIRONOLACTONE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Ceva Santé Animale | Spironolactone Ceva | spironolactone | EMEA/V/C/000105 For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs. |
Withdrawn | no | no | no | 2007-06-20 | |
Nova Laboratories Ireland Limited | Qaialdo | spironolactone | EMEA/H/C/005535 In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). |
Authorised | no | no | no | 2023-05-26 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for SPIRONOLACTONE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Morocco | 43132 | ⤷ Subscribe | |
Morocco | 43132 | COMPOSITIONS AQUEUSES DE SPIRONOLACTONE | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2017075463 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
SPIRONOLACTONE Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.